Paper Details

  1. Home
  2. Paper Details

The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation.

Author: BjarnasonN H, BlackD, CauleyJ A, CostaA, CummingsS R, EckertS, GlusmanJ E, GradyD, JordanV C, KruegerK A, LippmanM E, MorrowM, NickelsenT, NortonL, PowlesT J

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Raloxifene decreased the risk of invasive breast cancer by 76% in postmenopausal women with osteoporosis during 3 years of treatment. Raloxifene decreased the risk of estrogen receptor-positive breast cancer by 90%, but not estrogen receptor-negative breast cancer. Raloxifene increased the risk of venous thromboembolic disease but did not increase the risk of endometrial cancer.
Paper Details　
Original Abstract of the Article :
CONTEXT: Raloxifene hydrochloride is a selective estrogen receptor modulator that has antiestrogenic effects on breast and endometrial tissue and estrogenic effects on bone, lipid metabolism, and blood clotting. OBJECTIVE: To determine whether women taking raloxifene have a lower risk of invasive b...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1001/jama.281.23.2189

データ提供：米国国立医学図書館（NLM）

Raloxifene's Impact on Breast Cancer Risk

This large-scale randomized trial delves into the realm of women's health, investigating the effect of raloxifene, a selective estrogen receptor modulator, on the risk of invasive breast cancer in postmenopausal women with osteoporosis. It's like exploring a desert landscape, seeking to understand the influence of specific elements on the overall ecosystem.

Significant Reduction in Breast Cancer Risk

The trial found a significant reduction in the risk of invasive breast cancer among women taking raloxifene. It's like discovering that a specific plant in the desert can help protect against certain threats, creating a more resilient ecosystem.

Raloxifene's Benefits and Risks

While raloxifene demonstrated a significant benefit in reducing breast cancer risk, it also increased the risk of venous thromboembolic disease. It's like recognizing that even a beneficial plant may have unintended consequences, requiring careful consideration and balancing potential benefits and risks.

Dr.Camel's Conclusion

This research, like a treasure map leading to a hidden oasis, reveals the potential of raloxifene as a valuable tool in managing postmenopausal women's health. It highlights the importance of understanding the complex interplay of various factors in managing health risks and making informed decisions about treatment options.

Date :
  1. Date Completed 1999-06-24
  2. Date Revised 2022-04-10
Further Info :

Pubmed ID

10376571

DOI: Digital Object Identifier

10.1001/jama.281.23.2189

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.